High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Table 2
Univariate analysis of overall survival (OS) and clinicopathological characteristics in 62 patients with resectable pancreatic ductal adenocarcinoma.
Characteristics
Median OS (months) (95% CI)
Log-rank
value
Gender
0.05
0.824
Female
20.5 (18.9-22.0)
Male
22.4 (19.4-25.4)
Age (years)
0.244
0.621
≥60
24.6 (18.9-30.3)
<60
20.5 (18.6-22.4)
Location
0.055
0.815
Head
20.5 (17.2-23.8)
Body/tail
22.1 (19.7-24.5)
Maximum tumor diameter (cm)
2.231
0.135
<4
24.6 (17.6-31.6)
≥4
20.8 (17.0-24.5)
CA19-9 (U/mL) level
7.561
0.006
<37
26.8 (22.3-31.3)
≥37
20.2 (17.9-22.4)
Differentiation
6.036
0.014
Well/moderate
22.8 (19.1-26.4)
Poor
13.8 (6.97-20.6)
pT category
0.008
0.928
pT1+pT2
21.3 (18.4-24.2)
pT3+pT4
22.1 (18.0-26.1)
pN category
0.973
0.324
pN0
20.5 (17.8-23.2)
pN1
25.8 (17.7-33.9)
JAK2 expression
6.761
0.009
Low
24.6 (17.8-31.4)
High
20.1 (15.1-25.1)
Circumferential resection margin
R0
20.8 (18.3-23.3)
0.062
0.803
R1
24.6 (17.6-31.6)
Neural invasion
1.166
0.280
Yes
20.2 (15.1-25.3)
No
22.8 (17.5-28.1)
Vascular invasion
3.725
0.054
Yes
20.1 (17.3-22.9)
No
22.8 (17.3-28.3)
The value of the serum CA19-9 level, the histological differentiation, and the JAK2 expression is ≤0.05, which means that they were significantly associated with OS.
